WGS — GeneDx Holdings Corp.

Summary of GeneDx Holdings Corp. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $102.3 million, with exome and genome revenue at $90.6 million (up 27% year-over-year).
• Test Volume: 27,488 tests, reflecting a 34% increase year-over-year.
• Blended Average Reimbursement Rate (ARR): Approximately $3,300, which was lower than expectations due to product mix shifts.
• Adjusted Gross Margin: 69%.
• Adjusted Net Loss: $8.2 million.
• Impairment Charge: Non-cash impairment of $31.3 million related to the Fabric acquisition.

2. Strategic Updates and Business Highlights

• GeneDx is transitioning from multi-gene panels to comprehensive exome and genome testing, with a strong focus on increasing utilization in core markets.
• The company is integrating Fabric Genomics into its brand and refocusing on international growth opportunities.
• A new Reflex offering was launched to balance clinical demand with higher gross margins.
• The sales force has been expanded to enhance market penetration across various specialties, including NICU and general pediatrics.

3. Forward Guidance and Outlook

• Revenue Guidance: Updated to $475 million to $490 million for 2026, reflecting a 12% reduction from previous guidance.
• Volume Growth: Expected to be at least 30% for exome and genome testing.
• Gross Margin: Projected to be approximately 70%.
• Profitability: Aiming for adjusted profitability by the end of 2026, with a significant focus on core diagnostic business.

4. Bad News, Challenges, or Points of Concern

• Lower Revenue Expectations: Revenue was $12 million below expectations due to lower reimbursement rates and underperformance in non-core business lines.
• Competitive Pressures: A competitor's entry into the non-oncology rare diseases market with long-read options could impact GeneDx’s market share.
• Execution Issues: Challenges in managing the sales force transition and the mix of tests ordered (e.g., fewer parental comparator samples) affected reimbursement rates.
• Impairment Charge: The significant write-down related to the Fabric acquisition raises concerns about the integration and future profitability of that segment.

5. Notable Q&A Insights

• Management expressed confidence in the Q2 guidance, citing strong momentum and improved visibility into volume trends.
• The company acknowledged the need for better management of reimbursement dynamics and emphasized ongoing efforts to improve collection rates.
• Discussions highlighted the importance of the new Reflex product and its role in transitioning customers from exome to genome testing.
• Questions about competitive dynamics indicated that while GeneDx is aware of new entrants, they believe their existing strategy and market position remain strong.
• Management confirmed that the $25 million in operational expense cuts would not impact current run rates but are a recalibration of future spending to align with updated revenue expectations.

Overall, while GeneDx is experiencing growth in test volume and is strategically positioned for future opportunities, it faces challenges in reimbursement dynamics and competitive pressures that could impact its financial performance in the near term.